FDA Finds Undeclared Dexamethasone in Pain-Relief Product

Lab-confirmed dexamethasone in an unlabeled pain-relief product sold online signals a live enforcement posture from FDA that compliance and import surveillance teams should read carefully. The agency has advised against purchasing or using Qu Feng Huo Lou Dan, a product promoted for pain relief on multiple websites including www.newgreenusa.com and potentially in retail outlets, after laboratory analysis identified the undisclosed corticosteroid.

Dexamethasone is a prescription-grade steroid used clinically to reduce inflammation, but its presence in an unlabeled consumer product carries compounding risks: immunosuppression, hyperglycemia, muscle damage, and psychiatric effects. For any patient already on corticosteroid therapy, inadvertent co-exposure creates a clinically significant interaction that requires immediate professional assessment. FDA has noted that withdrawal from corticosteroids must be managed by a healthcare professional, not self-discontinued.

For QA directors and regulatory affairs leads, the enforcement read is direct. This detection falls within FDA's tainted supplement program, which targets products marketed as dietary supplements or conventional foods containing hidden pharmacologically active ingredients. The agency's standing position is that it cannot test every product in this category, placing the burden of supply chain diligence squarely on importers, distributors, and retailers who handle products in this space.

Label integrity and import surveillance are the operational pressure points here. Products promoted as "all natural" for pain relief, sexual enhancement, weight loss, or bodybuilding represent a documented risk category under FDA's tainted products framework. Compliance teams managing supplier qualification programs should treat this notification as a calibration point for incoming product review protocols, particularly for items sourced through online retail channels where label verification is inconsistent.

Adverse events or side effects associated with Qu Feng Huo Lou Dan should be submitted through FDA's MedWatch program, either via the online voluntary reporting form or by fax to 1-800-FDA-0178.

The agency's continued issuance of tainted supplement notifications through 2026 indicates that import surveillance and label-integrity controls remain active inspection focal points for firms operating at the dietary supplement and conventional food boundary.

Source: FDA Medication Health Fraud Notifications via FDA.gov RSS Feed, 25 August 2026.